(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

Uso de (+)--alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de distúrbios depressivos e distúrbios bipolares

IndeferidaInvention PatentPCT · US1997002597

Application data

Number

PI9708109

Type

Invention Patent

Filing

02/21/1997

Publication

07/27/1999

PCT

US1997002597

Progress at the INPI

Under appeal
  1. Filing02/21/97
  2. Publication07/27/99
  3. Examination
  4. Refused11/06/07
  5. Grant
  6. In force

The application was refused by the INPI on 11/06/2007. The invention was never patented.

Talk to a specialist

Latest action published by the INPI: 11/06/2007. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

Aventis Pharmaceuticals Inc.

US

Hoechst Marion Roussel, Inc.

US

See this company's full portfolio

Inventors

C. M. (pessoa física)

US

Technical data

IPC Classification

Priority claims

EP

96400591.2 · 03/21/1996

Abstract

Patente de Invenção: "USO DE (+)-ALFA-(2,3-DIMETOXIFENIL)-1-[2-(4-FLUOROFENIL)ETIL]-4-PIPERIDINAMETANOL NO TRATAMENTO DE DISTÚRBIOS DEPRESSIVOS E DISTÚRBIOS BIPOLARES" . A presente invenção refere-se ao uso de (+)- -(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidinametanol no tratamento de Distúrbios Depressivos e Distúrbios Bipolares.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Indeferimento

#9.2

Indefiro o presente pedido de patente, de acordo com Art. 36 da LPI (Lei 9279/96).

11/06/2007

RPI 1922

Alteração de nome deferida

#25.4

Alterado de: Hoechst Marion Roussel, Inc.

08/21/2007

RPI 1911

Alteração de sede deferida

#25.7

Sede alterada conforme solicitado na Petição nº 020070033918/RJ de 19/03/2007.

08/21/2007

RPI 1911

Conhecimento de parecer técnico

#7.1

12/19/2006

RPI 1876

Notificação de entrada na fase nacional - PCT

#1.3

07/27/1999

RPI 1490

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.